Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | NME2 | P22392 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7233932 | 0.85 | EGFR (0.61) | EGFRERBB2AURKAAURKBMAPT | |
| SCHEMBL7118735 | 0.83 | EGFR (0.51) | EGFRERBB2AURKBEPHX2MAPT | |
| SCHEMBL7234306 | 0.79 | EGFR (0.58) | EGFRERBB2AURKAAURKBMAPT | |
| SCHEMBL7235000 | 0.77 | EGFR (0.56) | EGFRERBB2AURKAAURKBMAPT | |
| SCHEMBL7239476 | 0.76 | EGFR (0.57) | EGFRERBB2AURKAAURKBMAPT | |
| SCHEMBL7123170 | 0.76 | EGFR (0.44) | EGFRERBB2 | |
| SCHEMBL7123173 | 0.76 | EGFR (0.44) | EGFRERBB2 | |
| SCHEMBL7129900 | 0.75 | EGFR (0.49) | EGFRERBB2 | |
| SCHEMBL7130779 | 0.75 | EGFR (0.39) | EGFRERBB2AURKBEPHX2 | |
| SCHEMBL7124289 | 0.75 | EGFR (0.52) | EGFRERBB2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | claimed |
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885NME2 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.